Canine Arthritis

Canine Arthritis

Osteoarthritis (OA) is a slow progressive disorder of synovial joints. OA specifically involves the imbalance between catabolic and anabolic processes (metabolism) resulting in erosion of joint cartilage, remodelling of subchondral bone, osteophyte formation and variable degrees of synovial membrane inflammation (synovitis).

OA is the most common form of arthritis and is present in 20% of dogs over one year of age. OA is also referred to as degenerative joint disease (DJD).

These changes in the metabolic balance in the joint lead to the following changes in the pathology of the arthritic joint.

•  Decreased synovial fluid quality (viscosity) – Due to defective synoviocyte metabolism the major component of synovial fluid, hyaluronan, has reduced molecular weight reducing its lubrication qualities. Additionally there is hypoxia, decreased pH and lactate accumulation in the synovial fluid.

•  Cartilage failure – Cartilage failure is both a primary cause of OA and a secondary outcome of the arthritic process (get the pdf here). Cartilage failure is characterised by softening, fibrillation, fragmentation and degradation of the cartilage matrix reducing its functional capacity.

•  Heightened inflammation (synovitis) / Immune response – Cartilage degradation products elicit t an immune response that provokes subsequent inflammation in the synovium, synovitis. The inflammatory response causes a release of noxious substances, which subsequently affect cartilage, bone and synovial fluid.

•  Vascular engorgement – The immune response can lead to lipid deposition and fibrin clots in synovial tissues and subchondral blood vessels. Subsequently, OA affected patients have hyperlipidemia, hypercoagulability and hypofibrinolysis. It has been shown that 60-70% of OA patients have hypercoagulability and hypofibrinolysis.

•  Cell necrosis, bone remodelling, bone necrosis. – Blood flow and nutrition to bone and synovial cells is compromised by lipid and fibrin occlusions resulting in ischaemia, cell necrosis, bone necrosis and joint pain.

Below is a comparison of the changes in an osteoarthritic joint next to a normal joint.


Coagulation, système immunitaire et os, les éléments oubliés de l’OA

L’OA est largement associée à des irrégularités dans le cartilage, le liquide synovial, le tissu synovial et l’inflammation associée. Comme indiqué dans la description de la pathologie ci-dessus, l’OA a d’autres éléments clés impliqués dans le processus d’arthrose comme ceux du système de coagulation, insuffisance osseuse et réponse immunitaire. Ces éléments ne sont souvent pas pris en compte dans le traitement de l’arthrose. Afin d’entreprendre un traitement de l’arthrose efficace, il est nécessaire d’avoir une vue holistique de tous les éléments sous-jacents.

La normalisation et l’équilibre dans une gamme d’activités métaboliques sont nécessaires et vitaux pour obtenir un traitement de l’arthrose couronné de succès.

Afin de développer des médicaments spécifiques à l’ostéoarthrose…. On doit se débarrasser de la pensée mise dans les médicaments antirhumatismaux ; l’évidence suggère que les premiers changements dans la matrice du cartilage ne sont pas inflammatoires. Mais la douleur et l’inflammation secondaire sont des résultats communs et tardifs des premiers changements dans le cartilage.




Click to view references

Arnoldi CC (1996) Development from osteoarthritis and nontraumatic osteonecrosis to osteoarthrosis. ARCO Newsletter 8(1):4-27

Francis DJ, Hutadilok N, Kongtawelert P, Ghosh P (1993) Pentosan polysulphate and glycosaminoglycan polysulphate stimulate the synthesis of hyaluronan in vivo. Rheumatol Int 13:61-64

Gardner DL (1983) The nature and causes of osteoarthrosis. Br Med J 286:418-424

Hamerman D (1993) Aging and osteoarthritis: Basic mechanisms. J Am Geriatr Soc 41(7):760-770

Hegemann N, Kohn B, Brunnberg L, Schmidt MF (2002) Biomarkers of joint tissue metabolism in canine osteoarthritic and arthritic joint disorders. Osteoarthritis Cart. 10, 714-721

McLaughlin R (2000) Management of chronic osteoarthritic pain. Veterinary Clinics of North America: Small Animal Practice 30, 933-949

Back to top

Sign up to our newsletter

Stay up to date with the latest developments from Cartrophen Vet